Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDActual EPS
Sorrento Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 7 | -$0.24 | -$0.24 | -$0.24 |
| Q2 2025 | 7 | -$0.21 | -$0.21 | -$0.21 |
| Q3 2025 | 7 | $2.76 | $2.76 | $2.76 |
| Q4 2025 | 7 | $0.42 | $0.42 | $0.42 |
| Q1 2026 | 9 | -$0.37 | -$0.37 | -$0.37 |
| Q2 2026 | 9 | -$0.23 | -$0.23 | -$0.23 |
| Q3 2026 | 9 | -$0.39 | -$0.39 | -$0.39 |
| Q4 2026 | 9 | -$0.17 | -$0.17 | -$0.17 |
| Q1 2027 | 6 | -$0.25 | -$0.25 | -$0.25 |
| Q2 2027 | 6 | -$0.26 | -$0.26 | -$0.26 |
| Q3 2027 | 6 | -$0.19 | -$0.19 | -$0.19 |
| Q4 2027 | 6 | -$0.16 | -$0.16 | -$0.16 |
| Q1 2028 | 7 | -$0.16 | -$0.16 | -$0.16 |
| Q2 2028 | 7 | -$0.15 | -$0.15 | -$0.15 |
| Q3 2028 | 7 | -$0.09 | -$0.09 | -$0.09 |
| Q4 2028 | 7 | -$0.09 | -$0.09 | -$0.09 |
| Q1 2029 | 9 | -$0.15 | -$0.15 | -$0.15 |
| Q2 2029 | 9 | -$0.15 | -$0.15 | -$0.15 |
| Q3 2029 | 9 | -$0.09 | -$0.09 | -$0.09 |
Sorrento Therapeutics, Inc. Earnings Date And Information
Sorrento Therapeutics, Inc. last posted its earnings results on Friday, August 11th, 2023. The company reported $-0.17271 earnings per share for the quarter, missing analysts' consensus estimates of $-0.15 by $0.02271. The company had revenue of 15.03 M for the quarter and had revenue of 62.84 M for the year. Sorrento Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-1.37 diluted earnings per share) and currently has a price-to-earnings ratio of -0. Sorrento Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 13th, 2025 based on prior year's report dates.
Sorrento Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/11/2023 | Q2 2023 | N/A | -$0.17 | N/A | $22.60 M | $15.03 M |
| 05/15/2023 | Q1 2023 | -$0.16 | -$0.26 | -0.1 | $20.00 M | $16.25 M |
| 03/15/2023 | Q4 2022 | N/A | $0.00 | N/A | $18.22 M | $15.59 M |
| 11/08/2022 | Q3 2022 | -$0.25 | -$0.20 | 0.05 | $13.60 M | $17.40 M |
| 08/15/2022 | Q2 2022 | -$0.23 | -$0.55 | -0.32 | $18.75 M | $11.46 M |
| 05/05/2022 | Q1 2022 | -$0.25 | -$0.12 | 0.13 | $19.75 M | $18.39 M |
| 03/11/2022 | Q4 2021 | -$0.29 | -$0.47 | -0.18 | $12.54 M | $13.08 M |
| 11/05/2021 | Q3 2021 | -$0.21 | -$0.40 | -0.19 | $10.18 M | $12.06 M |
| 08/06/2021 | Q2 2021 | -$0.20 | -$0.57 | -0.37 | $8.37 M | $13.51 M |
| 05/05/2021 | Q1 2021 | $0.38 | $0.01 | -0.37 | $18.23 M | $14.26 M |
| 02/19/2021 | Q4 2020 | -$0.23 | -$0.28 | -0.05 | $1.01 B | $11.51 M |
| 11/06/2020 | Q3 2020 | N/A | -$0.33 | N/A | $10.31 M | $11.75 M |
| 08/04/2020 | Q2 2020 | -$0.24 | -$0.36 | -0.12 | $7.90 M | $9.01 M |
| 05/11/2020 | Q1 2020 | -$0.20 | -$0.36 | -0.16 | $10.00 M | $7.72 M |
| 03/02/2020 | Q4 2019 | N/A | -$0.34 | N/A | $6.60 M | $13.03 M |
| 11/08/2019 | Q3 2019 | N/A | -$0.49 | N/A | $7.10 M | $5.78 M |
| 08/09/2019 | Q2 2019 | -$0.40 | -$0.46 | -0.06 | $7.50 M | $6.48 M |
| 05/15/2019 | Q1 2019 | -$0.35 | -$0.88 | -0.53 | $8.02 M | $6.14 M |
| 04/29/2019 | Q4 2018 | N/A | -$0.41 | N/A | N/A | $6.93 M |
| 11/09/2018 | Q3 2018 | -$0.19 | -$0.40 | -0.21 | N/A | $4.11 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Sorrento Therapeutics, Inc. Earnings: FAQ's
Sorrento Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 13th, 2025 based offlast year's report dates.
The conference call for Sorrento Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Sorrento Therapeutics, Inc.'s latest earnings report can be read online.
Sorrento Therapeutics, Inc. (:SRNE) has a recorded annual revenue of $62.84 M.
Sorrento Therapeutics, Inc. (:SRNE) has a recorded net income of $-572,843,000.Sorrento Therapeutics, Inc. has generated $-1.37 earnings per share over the last four quarters.
Sorrento Therapeutics, Inc. (:SRNE) has a price-to-earnings ratio of -0 and price/earnings-to-growth ratio is -0.